The greater in vivo efficacy of ADH-6 compared to ReACp53 correlates well with their relative capacities to dissociate intracellular mutant p53 aggregates (Fig. 3 and Supplementary Figs. 7–9) and to induce toxicity in mutant p53-bearing cancer cells (Fig. 4 and Supplementary Fig. 11), as well as with their relative in vivo stabilities. This evidence concerns the gene TP53 and cancer.